What is claimed is:

1. Use of an effective amount of hypericin in the manufacture of a medicament for use in combinatorial therapy for treating CTCL, wherein said medicament is to be administered together with a form of visible light photodynamic therapy.

2. The use of claim 1, wherein the effective amount of hypericin is an ointment comprising less than 1% hypericin.

3. The use of claim 1, wherein the form of photodynamic therapy comprises an administration of escalating doses of visible light.

4. The use of claim 3, wherein the escalating doses of visible light starts at about 5 J/cm^2 and increases to a maximum dose of about 12 J/cm^2.

5. The use of claim 4, wherein the escalating doses of visible light is to be increased by about 1 J/cm^2 from about 1 week to about 3 weeks.

6. The use of claim 4, wherein the escalating doses of visible light will continue until about 12 J/cm^2 or until light erythema of the lesions is observed.

7. The use of claim 2, wherein the effective amount of hypericin ointment is to be administered at least once weekly.

8. The use of claim 2, wherein the effective amount of hypericin ointment is to be administered at least twice weekly.

9. The use of claim 8, wherein the hypericin ointment is to be applied, then followed by 12-24 hours of absorption into the skin, while covered, and then followed by a light exposure.

10. The use of claim 1, wherein application of the effective amount of hypericin and the form of visible light photodynamic therapy is to be continued twice weekly for at least 6 weeks.

11. The use of claim 1, wherein the effective amount of hypericin is to be administered more frequently than the form of visible light photodynamic therapy.

12. The use of claim 1, wherein the effective amount of hypericin is to be administered less frequently than the form of visible light photodynamic therapy.